U.S. FDA plans ultra-fast review of three psychedelic drugs following Trump directive
CTV News
—
The U.S. Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest indication of the Trump administration’s commitment to the experimental treatment approach.
- US FDA plans ultra-fast review of 3 psychedelic drugs after Trump directive South China Morning Post —
- FDA grants quick review for 3 psychedelic drug trials NBC News —
- FDA fast-tracks psychedelic drug research following Trump executive order CNBC —
- US FDA moves to fast-track psychedelic drugs after Trump order - Reuters Reuters —
- FDA plans fast review of 3 psychedelic drugs following Trump directive Boston Globe —